Company Name
LAMINAR PHARMACEUTICALS

Activity
Transformation of medicine therapies developing innovative and pioneering drugs.

CIF
B57451171

Sector
BioPharmaceuticals

Address
Ctra. de Valldemossa Km. 7,4. ParcBIT. Edificio 17. 2º C-8 - Palma de Mallorca

EPM Joining Date
04/06/2020

Creation Date
17/10/2006

Founders Pablo V. Escribá, Vicenç Tur

Auditor
KPMG

Investors email contact
info@laminarpharma.com

Presenting Partner
Fellow Funders

Company profile

Continuous investment in Drug research and development (R&D) with high quality standards. 

We are a committed company, our vocation is serving to society, people are the most valuable asset. We want to provide solutions to unmet health needs. We want to help those most in need and improve their quality of life

Pablo V. Escribá
CEO

On the Road to BME Growth

  • 23/07/2020 - Registered Advisor
  • 29/09/2020 - Transformation in PLC

Relevant data

(thousand of Euros)201920202021*2022*
Net worth10.86110.995,7719.03736.415
Net business turnover450144,86200200
Financial debt3.367,615.444,834.5542.491
Ebitda-160,91-865,47-2.069-3.286
Net Profit-379,48-1.448,75-2.096-2.877
Average number of employees09192127
* Proyection

 

Investment Rounds

Date Status Amount Minimum Ticket
11-10-2021Open1.200.000758,00

 

Business Model

License and supply to Big pharmas worldwide, under a B2B exploitation model

Competitive advantage

Development of oncological drugs as a new-generation of “First in class medicines” based on the innovative technology called MLT (Membrane lipid therapy), strongly patented worldwide. Our therapeutic platform uses highly safe therapeutic lipid molecules to improve the quality of life of people affected by some incurable diseases.

Scalability

Medicines innovation in the best interest of mankind

Contact Us

You are just one step away from growing your company